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ABSTRACT 
Q Fever Subunit Vaccine. (May 2015) 
 
Caitlyn Cowen 
Department of Biology 
Texas A&M University 
 
Research Advisor: Dr. James Samuel 
Department of Microbial Pathogenesis and Immunology 
 
Q fever is a globally important zoonotic infection caused by the obligate intracellular bacterium 
Coxiella burnetii.  Since C. burnetii is both an occupational hazard to humans interacting with 
naturally infected animals and a potential biothreat agent, a safe and effective vaccine is an 
important goal. Despite one being approved for use in Australia (Q-Vax®), this has not been 
licensed elsewhere due to complications with pre-sensitised individuals. As a result, research into 
developing a safe and effective vaccine against Q fever remains a priority in reducing the global 
impact this bacteria has on both livestock and human health. The goal of this project is to isolate 
and purify dominant antigenic Coxiella proteins expressed in Escherichia coli. These proteins 
will then be used as subunit vaccines that will be test the ability to confer protective immunity 
against Q fever in a mouse model large particle aerosol infection. 
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NOMENCLATURE 
 
 
Luria-Burtani broth with Kanamyacin- LB Kan 
Base pairs- bp 
Supernatant- SN 
Kilodaltons- kDa 
Isopropyl β-D-1-thiogalactopyranoside- IPTG 
 
Small Ubiquitin-like Modifier- SUMO 
 
Polymerase Chain Reaction- PCR 
 
Enzyme-Linked Immunosorbent Assay- ELISA 
 
Histidine- HIS 
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CHAPTER I 
INTRODUCTION 
 
Coxiella burnetii is a small, Gram-negative bacterium that is the etiological agent of Query fever 
(Q fever). This obligate intracellular pathogen is capable of withstanding extreme environmental 
pressures; high temperatures, ultraviolet light exposure, osmotic pressure, and standard 
disinfectants. C. burnetii has a very low infectious dose of 1-10 bacteria and can form a spore-
like small cell variant to stay dormant in the environment if a host is not available. Once inside a 
eukaryotic cell, the bacterium forms an acidic vacuole and uses it to multiply. The pathogen 
undergoes antigenic phase variation. Phase I is the most virulent in animals. A switch to phase II 
is the result of the surface lipopolysaccharides truncation which results in reduced virulence (1).  
 
As the causative agent of Q fever, a zoonotic bacterial disease, it is an important public health 
goal to have a vaccine that can confer protective immunity for individuals at high risk for coming 
into contact with the bacteria. Since livestock are the natural reservoirs of the bacteria, those who 
work with livestock have the greatest risk of infection (3). Infection often occurs from inhaling 
contaminated aerosols containing from bodily fluids or feces of an infected animal (3). At a more 
global scale, “C. burnetii is also classified as a “Category “B” critical biological agent” by the 
Centers for Disease Control and Prevention and is considered a potential weapon for 
bioterrorism” (3).  C. burnetii has a low mortality rate (1-11%), but there has been a steady 
increase in the number of cases each year. It is essential to have protective measures against this 
bacterium that is so infectious and has the potential to be used as a biological weapon. It is 
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especially important to be able to prevent infection of our military that cannot afford to have an 
outbreak of Q fever while deployed.  
 
Diagnosis of Q fever is difficult and is often confused for the flu due to its similar primary 
symptoms; fever, vomiting, and headache. Consequently, patients are often misdiagnosed and do 
not receive the appropriate treatment. There are two forms of the infection, acute and chronic. 
Acute Q fever is normally mild but some experience complications such as pneumonia, hepatitis, 
or meningoencephalitis (1).  Chronic Q fever occurs in less than five percent of those with a 
previous acute infection. It can develop weeks or years later and normally affects pregnant 
women, immunosuppressed people, or those with a pre-existing heart defect (5). Chronic Q fever 
is severe and causes life-threatening damage to the lungs or most commonly to the heart 
(endocarditis) (3).  
 
Currently there is a whole cell vaccine against C. burnetii licensed for human use in Australia 
which is effective in providing protective immunity, but they are not approved in the U.S. due to 
their reactogenic effects.  The whole cell vaccine induces local to severe systemic reactions in 
individuals that have been previously exposed to C. burnetii (2). This means that a skin test must 
be given to patients prior to immunisation. It is too costly and time consuming to test each 
individual for previous exposure to C. burnetii (3). Therefore, a safe and efficient vaccine is 
needed to provide immunity and prevent infection without the risk of adverse reactions.  
 
The goal of the project is to create a recombinant protein subunit vaccine that can elicit an 
adaptive immune response to successfully generate a protective antibody and T cell population. 
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T cells are thought to be necessary for a robust immune response that will produce memory cells 
for future encounters with the bacterium (7).  CD8 T cells are effective against intracellular 
pathogens. Previous studies have found some Coxiella burnetii proteins stimulated an antibody 
response after the whole cell vaccination was given. Information on the proteins cross reactivity, 
function in the cell, and potential for native purification were used to choose a small group of 
candidate proteins. Once the proteins have been successfully expressed in E. coli and purified 
they will be tested for immunological responses in a mouse model system.  
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CHAPTER II 
METHODS 
Literature Review of Subunit Vaccine Candidates 
In order to choose proteins that could potentially be antigenic, a review of some previously 
compiled data was done. Some early studies had shown that protection could be provided by 
subunit protein vaccines, including Williams et al. Which identified a Coxiella burnetii porin 
protein (P1) that provided protection to mice from a lethal challenge (8). Another protein that 
provided full protection in guinea pigs and mice was a large GroEL protein (67 kDa) (10). 
Purified Coxiella burnetii LPS has also been shown to provide protection in mice (9). However 
in a sublethal challenge model in BALB/c mice a singular protein were not found to provide 
protection, so a combination of dominant antigens was postulate to provide significant protection 
(11). The most important quality in a protein for our project was the ability to be purified so that 
immunogenic analysis could be performed. All four proteins chosen had previously been 
purified. Other qualities that were compared included if there was reactivity with hyperimmune 
sera, the molecular mass, and if the protein had been characterized in previous studies. Since a 
combination of proteins is most likely what will be needed for full protection, a variety of 
proteins with different qualities were favorable. The first protein chosen for this project, 
CBU_0891, fit the criteria because it was previously in a vaccine trial, has infection derived 
reactivity with human sera, and was characterized as an exported membrane associated protein 
composed of 312 amino acids (6).  Our second antigen, CBU_1249, also has reactivity with 
human sera and is composed of 203 amino acids (6). It was chosen as a candidate to add 
diversity of function, it is annotated as a DNA-binding protein. CBU_1115 is annotated as a 
hypothetical protein comprised of 105 amino acids and has reactivity with human sera. This 
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candidate was chosen mainly because it has been previously tested as a Q fever diagnostic (6). 
The final candidate, CBU_1716, is predicted to be a glycine cleavage T protein composed of 391 
amino acids, it also adds variation to the functions of each candidate protein (6).  Since these 
proteins will most likely be combined in a later study to test for protection, a variation of 
functions could be an advantage when stimulating an immune response.  
 
PCR Primers 
Primers were designed by copying the gene sequence and amino acid sequence of each candidate 
protein into Microsoft word. The amino acid sequence was then copied into predisi.com to 
predict if there was a sec dependent secretion peptide on the C. burnetti sequence. If a sec 
sequence was present, it was highlighted on the sequence in Word and base pairs after the 
sequence were designed into the primer. A predicted primer around 15-25 base pairs was copied 
into an oligocalculator, such as http://www.basic.northwestern.edu/biotools/oligocalc.html. 
Bases were added or taken away until the melting temperature 50°C was reached. The reverse 
primer was designed using the same process and then putting the primer in a reverse compliment 
calculator, http://www.bioinformatics.org/sms/rev_comp.html. C. burnetii gene sequences of 
interest were amplified using PCR. Reagents used for PCR are from the pET SUMO TA cloning 
kit (Invitrogen) with the addition of the previously designed primers and template DNA.  
Amplification was performed in a 50 µl reaction volume consisting of 1µl template DNA, 5 µl 
10X PCR Buffer, 0.5 µl dNTP mix (10mM), 1 µl primer 1, 1 µl primer 2, 40.5 µl RNase free 
water, and 1 µl Taq DNA Polymerase.  
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Transformations 
The amplified PCR product was cloned into the SUMO vector through a ligation reaction (Figure 
1.1). Ligation reagents from the pET SUMO TA cloning kit were combined with fresh PCR 
product to a reaction volume of 10 µl; 1 µl fresh PCR product, 1 µl ligation buffer, 2 µl SUMO 
vector, 5 µl water, 1 µl T4 DNA Ligase. The ligation reaction was incubated overnight at 15°C.  
The construct from the ligation was transformed into One Shot Mach1-T1 competent E. coli 
cells. Competent cells were thawed on ice, 2 µl of the ligation reaction was added to the 
competent cells and incubated on ice for 30 minutes. Heat shock was used for 45 seconds in the 
heat block at 42°C, then cells were put back on ice for 2 minutes and 250 µl of warm S.O.C. was 
added. Cells were incubated at 37 °C on the rotator for 1 hour, plated on warm LB Kan plates 
(50 µg/ml) with 250 µl room temperature S.O.C., and incubated overnight at 37°C. 
Colony PCR was used to analyze transformants. Each sample colony was added to 50 µl 5 % 
Chelex and incubated at 100°C for 10 minutes. This was then spun down for 3 minutes at 16,000 
x g. The colony PCR reaction consisted of 3 µl colony and Chelex mixture, 5 µl 10x PCR buffer, 
0.5 µl dNTP mix (10mM), 1 µl SUMO forward primer 1, 1 µl gene specific reverse, 38.5 µl 
RNase free water, and 1 µl Taq DNA Polymerase. Colony PCRs were visualized with a 1% 
agarose gel. The GeneJet plasmid prep mini kit (Thermo Scientific) was used isolate the plasmid 
for transformation and to prepare colony PCR confirmed constructs for sequencing. 
Chromatograms and sequences were analyzed to confirm the plasmid was present and in the 
correct orientation.  
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Protein Purification 
Sequence confirmed constructs were transformed into BL21(DE3) One Shot E. coli cells 
(Invitrogen). The constructed plasmids have an inducible promoter that expresses the gene 
product in the presence of Isopropyl β-D-1-thiogalactopyranoside (IPTG). The sequence 
confirmed constructs were cultured by inoculating 50 ml LB with Kanamyacin (50µg/ml) with 
one single colony and incubating overnight at 37 °C. Fresh LB Kan (500mL) was inoculated 
with 2.5ml of overnight culture and grown to an OD of 0.8 (about 1 hour and 15 minutes). 
Culture was then induced by adding 500 µl IPTG and growing 4 hours at 37 °C.  Cells were 
harvested by centrifuging at 10,000 rpm for 20 minutes. The pellet was washed with PBS and 
stored in 1 mL fractions at -80°C until purification. The pellet was thawed and microcentrifuged 
at 6000 rpm for 5 minutes, then resuspended into a buffer mixture consisting of 886 µl 
suspension buffer, 100 µl lysozyme (fc 1 mg/mL), 0.4 µl benzonase nuclease, and 10 µl protease 
inhibitor (1x). Different suspension buffers were used depending on the type of purification, the 
standard suspension buffer contained 50mM Tris, 50 mM NaCl and was at a pH of 7.5. Cells 
were disrupted by sonicating with a 3mm microtip in 5 minute cycles of 10 seconds on, 5 
seconds off until the solution was clear. The solution was centrifuged at 16,000 x g for 20 
minutes at 4°C. The soluble lysate was separated from the pellet and both were purified using 
HisPur Ni-NTA Resin batch method. This method uses an affinity column with nickel resin that 
binds to the 6xhis tag that is on each protein. Purified protein was analyzed using an SDS Page 
Gel.  
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CHAPTER III 
RESULTS & DISCUSSION 
 
PCR Primers 
Coxiella burnetii antigenic candidates were chosen based on an extensive review of the 
literature. Primers were designed to recombinantly express these proteins in a pET SUMO E. coli 
expression system, Figure 1.1 is the vector map of pETSumo from Invitrogen. The vector 
contains a lac operon, His tag, and a Kanamyacin resistance gene. Figure 1.2 shows Coxiella 
burnetii genes that were amplified using PCR and then run on a 1% agaraose gel; CBU_0891 
(939 bp) and CBU_1143 (351 bp) are in the correct vicinity of their molecular weight. However, 
CBU_1249 (612 bp), and CBU_0612 (498 bp) are a little higher than they should be.  Figure 1.3 
is a PCR of four additional Coxiella burnetii genes; CBU_0781 (1017 bp) and CBU_0140 (1242 
bp) are at the correct molecular weights, the band at CBU_0311 (759 bp) is around 1000 base 
pairs which is too high, and CBU_0383 (639 bp) did not show up at all. The PCR for CBU_0383 
was performed again with a PCR program changing the melting temperature to 51 °C, which was 
 the melting temperature for this particular primer. The PCR was successful and the band was at 
the correct molecular weight marker as seen in Figure 1.4.   
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Figure 1.1 From Invitrogen. Plasmid map of 
vector used to clone Coxiella burnetii genes and 
express recombinant proteins.  
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Transformations 
Plasmids transformed into Mach1 E. coli cells grew small, white circular colonies with no 
discernable elevation. Colony PCR of a few colonies from each plate was used to confirm the 
plasmid was present. The primers used for the colony PCR reaction only read in one direction, 
therefore products are only observed if the construct is in the correct orientation. Colony PCR 
confirmed constructs were sent for sequencing. Figure 2.1 is a colony PCR of plasmid 
CBU_0891 six colonies from the transformation were selected. All colonies from CBU_0891 
showed the plasmid was present and these were sent off for sequencing. Figure 2.2 shows a 
colony PCR of CBU_1249. Three lanes D, E, and F show a faint band and these three colonies 
were sent off for sequencing.  
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Protein Purification 
The constructed plasmids have an inducible promoter that expresses the gene product in the 
presence of IPTG. Cultures grown in the presence of IPTG were compared with uninduced 
cultures by running them on a 4-12% Bis-Tris protein gel.  Figure 3.1 shows these eight fractions 
from four separate inductions. Although lane B is smudged, when comparing it to the induced 
lane C it is evident that more protein was expressed in the induced culture. When looking at the 
gel at 55 to 60 kDa there is a band that wasn’t present in the uninduced lane, the induced lane 
also has thicker bands at 38 and 50 kDA which means more expression occured. When 
comparing lanes D and E/ F and G a new band of expression occurred around 20 kDA and 30 
kDA respectively. Lanes H and I did not have any new bands of expression in the induced lane, 
but the induced lane had thicker bands and therefore more expression of protein. Purifications 
under all conditions where done using a nickel packed affinity column, which binds to the 6xhis 
tag in each protein. Purifying with denaturing versus native conditions for CBU_1716 and 
CBU_1115 was not successful; therefore a salt gradient purification was performed on each to 
determine if that was a better choice for this particular protein. Figure 3.2 shows the protein gel 
16	  
	  
of the salt gradient purification done on CBU_1716 protein. The gel had protein at the correct 
molecular weight when including the SUMO tag that is still on the protein, 38 kDA plus 11 KDa 
(Sumo) makes the protein around 50 kDA. Although protein was purified at each concentration 
of salt, the lowest salt concentration, 0.1 M NaCl acquired the most protein. Figure 3.3 is the 
protein gel of the salt gradient purification for CBU_1115. At the highest salt concentration, 1M 
KCl, a faint band is seen just below 31 kDa. CBU_1115 protein should be around 20 kDa 
including the sumo tag. This protein purification was not successful and a pH gradient will be the 
next purification tried on CBU_1115.  
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Immunization 
In order to test the efficacy of each vaccine, the purified proteins combined with an adjuvant, 
CpG, will be subcutaneously injected into female BL57/6 mice. This adjuvant favors a Th1 
immune response. This will be followed by a boost 2 weeks later, and resting for an additional 5 
weeks to allow innate activation to subside. The challenge will be done with 1x105 C. burnetii 
RSA 493. The mice will be euthanized after 2 weeks and serological responses will be measured 
for specific antibody titers, immunoglobulin antibody class switching, and T cell memory recall. 
These tests will help determine the type of immune response induced. If successful, the mice that 
were vaccinated with the recombinant protein vaccines would demonstrate a similar protective 
response to the positive control mice that were vaccinated with the whole cell vaccine. While the 
negative control animals will manifest disease.  
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CHAPTER IV 
CONCLUSION 
 
 
During the cloning process, a total of 14 primers were designed. PCR cloning was unsuccessful 
for CBU_1645, CBU_1184, CBU_1143, and CBU_0952. The primers for each of these need to 
be redesigned. Colony PCR from the transformations was only successful for CBU_0891 and 
CBU_1249. This technique was hard to perform accurately and sequencing was also done on 
CBU_1115 and CBU_1716 constructs that were not verified by colony PCR. The sequencing 
results confirmed each of the four constructs (CBU_0891, CBU_1249, CBU_1115, and 
CBU_1716) were successfully cloned into the pET SUMO vector and transformed into E. coli 
for expression of protein. Each of the four protein candidates have been recombinantly expressed 
in E. coli by an inducible promoter. Each initial induction successfully produced enough protein 
for purification with the Ni resin affinity column. Purification of these proteins is still ongoing as 
each protein is different and requires a different purification protocol. C. burnetii proteins are 
difficult to purify due to their extreme isoelectric points, this is most likely due to the 
intracellular lifestyle of C. burnetii thriving at a low pH. Several different methods of 
purification are being used on each candidate antigen. CBU_1716 has been successfully purified 
using a salt gradient purification. This protein will be added to the ongoing immunization study 
that was designed to test the protective efficacy of subunit antigens against a C. burnetii aerosol 
challenge. Once the other candidates are purified they will also be added to an immunization and 
protection study.  
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APPENDIX  
 
Candidate Antigen Forward Primer Reverse Primer 
CBU_0140 ATG CCG AAA AAT CCA GAT 
AAA 
TCAAAAATTTCCTTGGAACCA 
CBU_0311 GGC GGT CCT GAT ATC C TTAGATATTGAACAGGTAATTA 
CBU_612 CAA ACG GTT GGG CTT GTC TTATTTCAATGCTGATACAAC 
CBU_0781 ATG AGT AGA CGT GAG ACT TCACCGAGGACTAGACA 
CBU_0891 
GTG AAA CGG TAT CTT TTT 
TTT 
TCAAGGCAGGCTCTTTAAAA 
CBU_0952 GAA AAT CGC CCC ATT TTA A CTATTTATTTAAAAAAGTCGCC 
CBU_1115 
ATG TCA AAA TTT TTA CAC 
CGT 
TCAAGATTTATTCTCTCTATC 
CBU_1143 CAA GCG CCG CAT CCG TTAAATCGAATCGATCGTGC 
CBU_1184 TTG CGC TTA CAA AGA GTC T TTAGGAAGGAATTTCCTGG 
CBU_1249 ATG ACG GAA AAT GCG ATC TCAATGATTAGTTCCTGAAAAA 
CBU_1645 
ATG ATA GAA AAA TCG CAA 
CG 
TCATTCCTGCGAAGCAG 
CBU_1716 
ATG CCT TTG CAT TAT GGA 
TC 
TCAAAATGTTTTTTTACCACG 
CBU_1718 
ATG GCT GCA AAA GTT TTA 
AAA 
TTACATCATGCCGCCC 
CBU_1910 GCC CCC TCT CAA TTC A TTACTTTTCTACCCGGTC 
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Sequencing Data CBU_0891 
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CBU_0891_Forward Sequence 
NNNNNNNNAANNNNNNGANNNNNNNNGGACATGGAGGATAACGATATTATTG
AGGCTCACAGAGAACAGATTGGTGGTTCAAGGCAGGCTCTTTAAAAGCTCATC
GGCCTCCTGGCGCTGTTCTTCATTCCCCTGTTCGCTTACCTGCTTGAGCACTTTA
CGCGCTGATACCGGGTCTTCCATCGCAATATAAGTCCGAGCCAGATTAATTTTC
GCGGGAATACTTTCAGCACTTCCCATGTAATCATATTCCGCTTCGTCAGCGCCG
CCAATCGCTGGTTGATCATCCAAAACCCTGCGGTTTTTTTGATTTTTTCTTTTAC
GCGGCCAAAGTGCCCACNGTATTAGAAGTAGAGCAACGAACATCCCACCGATA
GCTGCCCTATACCCATTTTCTCCTAAAATTTGCTTTAAATACGCAATCCATCCGT
TAAAAGAGCTTTGGGATGGAGGATTTTGGGGCTGTAGTTGGGAGACAGGGTGG
CTGCCTTGTTTGAGTTGGACTAATTCTTGATTGAGCAACGTCNCTNCTTTTTCCA
AGTTTTGTAATCGNTGCTGTAATTGTTGGTTTTGANTTATTCAGTTGCTCCAAAC
GACCCGTCTGTTTGCTGCNGAAATTGCAAACTGTTTTGGTTCCATTTGAGTAAAT
TTCTGCCTGAAGCATAGCCGAAANAGTCATGGCTNCACANCCNNNNNNNAGCG
GAATGCATAANACGTNNTCCGAACTTGGNCCCTGNTTTCAGGAACCCNACTTTT
TTTA 
CBU_0891_Reverse Sequence 
NNNANTNNNAANNNNNNNNNANNANNNGGACATGGNAGGATAACGATATTTA
TTTGAGGCTCACAGAGAACAGATTGGTGGTTCAAGGCAGGCTCTTTAAAAGCTC
ATCGGCCTCCTGGCGCTGTTCTTCATTCCCCTGTTCGCTTACCTGCTTGAGCACT
TTACGCGCTGATACCGGGTCTTCCATCGCAATATAAGTCCGAGCCAGATTAATT
TTCGCGGGAATACTTTCAGCACTTCCCATGTAATCATATTCCGCTTCGTCAGCGC
CGCCAATCGCTGGTTGATCATCCAAAACCCTGCGGTTTTTTTGATTTTTTCTTTT
ACGCGGCCAAAGTGCCCACAGTATTAGAAGTAGAGCAACGAACATCCCACCGA
TAGCTGCCCTATACCCATTTTCTCCTAAAATTTGCTTTAAATACGCAATCCATCC
GTTAAAAGAGCTTTGGGATGGAGGATTTTGGGGCTGTAGTTGGGAGACAGGGT
GGCTGCCTTGTTTGAGTTGGACTAATTCTTGATTGANCAACGTCACTACTTTTTC
CAAGTTTTGTAATCGTTGCTGTAATTGNNGGNTTTTGACTATTCAGTTGCTCCAA
ACGACCGTCTGTTTGCTGCTGAAATTGCAAACTGTTTTGGTTCATTTGAGTAAGT
TCNGCCTGAANCATAGCCCGAANAGTCANGNNTCACAACCGCGTTANCGGATG
CANANACNTCCTCCGTACTTGGTCCTGNTTCANGCACCGACNTTTTAGANCCNG
GGGNANNCGACCNNNNGGGTGGCANTTNTAGGTGCCNGATTTGANCTGTATNN
NCGGGACNTTTGGTTTTCNNNNNCTCTGNNACNTNNNNNNCNNGGNNNTNNTC
NNNTCTNNAGGGGTTNNNGNNNNNNNANNNNNCN 
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Sequencing Data CBU_1249 
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CBU_1249_Forward Sequence 
NNNNNANNNNNNNNNNNNCNNNNNNNGATTTTGGANTGGAGGATAACNATA
TTATTGAGGCTCACAGAGAACNGATTGGTGGTATGACGGAAAATGCGATCGA
TATGGAAATCAATCTCCCACGTTCGGACAGCGCCGCGAAGACGCCCGGTATCC
TCTTGCGCGAGGCTCGCCAGGCGAANAATCTTCAGCAAAGCGATGTCGCGAA
AGAGATACGGCTTATCATTCNNTGGGTTAAAGATCTTGAGCAAGACGATTATT
CTCATGTTCCCGCGTTAATTTACGTCCGCGGTTATTTACGTGGTTATGCCCGTT
ATGTGGGTATTTCTCCCGATGAGGTGATGGCAGCTTTTGATGAGATGGGATTG
GAATAANATTTCGAGCGAGTGAAAGCCCAANTANAAAGACCCGTGAAACACC
ACGCGGTGCCCGTCGTCTTAAGATCGA 
CBU_1249_Reverse Sequence 
NNNNNNNNNNNNNNNNNNNNNNANANNTGGACATGGAGGATAACGATATTA
TTGAGGCTCACAGAGAACAGATTGGTGGTATGACGGAAAATGCGATCGATAT
GGAAATCAATCTCCCACGTTCGGACAGCGCCGCGAAGACGCCCGGTATCCTCT
TGCGCGAGGCTCGCCAGGCGAAGAATCTTCAGCAAAGCGATGTCGCGAAAGA
GATACGGCTTAGCATTCAATGGGTTAAAGATCTTGAGCAAGACGATTATTCTC
ATGTTCCCGCGTTAATTTACGTCCGCGGTTATTTACGTGGCTATGCCCGTTATG
TGGGTATTTCTCCCGATGAGGTGATGGCAGCTTTTGATGAGATGGGATTGGAA
GAAGAGTTCGAGCGAGTGAAAGCCGAAGTAGAAAGACCCGTGAAACACCAC
GCGGTGCCCGTCGTCTTAAGATCGAAACGGATGATTAACGGCAAAATGGTTC
GGTGGGTTACGGTTATTTTATTAGTGGCGCTGATTGTCTCTGTGGGCGTTTGGT
GGCAAGGCAAAAAACATATTCTTTGGGCAATTGCAATCAGTTATTTCTTCGCC
CGCAAGNAGAATTTGCCCTTAAAACAAACGTCAGTGAATTCAGTGAATACTA
AATAAAACGATCAACACAAATTTGACGGAGCAACCCCACGGGCCATAAAATA
CAAGAATAAAGATAACTTTTTCAGGAACTAAATCATTGAAGACAAGCTTTAG
GGTATTTTATTCNGGCGNNAAGTNGCTGTCNGGTGATTGCTGNCTACTTTANT
CGTANCNNCCACCACCCACCACCACCTGAGATCCNGCTGCTTAANCAAAGCC
CNGANNNNNNCTGNNNNGNCNNCTTNCCCACCNNNCTGNAGCNNNNNNCNN
ANNNNNNAANCCCCCCNTNNG 
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Sequencing CBU_1115 
CBU_1115_Forward Sequence 
NNNNNNNNNNNNNNNNNNNNNANNNNNNCATGGAGGANAACGATATTATTGAG
GCTCACAGAGAACAGATTGGTGNGTATGTCAAAATTTTTACACCGTTTATGGGAA
GGAATCATGCCAATTGTGGGCATGATTGTTTTCGTTATTCTTTTTATCGTGGGGAT
ATTTATTTTTTCCTATCTTCTAATCATCGCTGCCGTTATTGGATTGATACTTTTTAT
CATCGCCTTTATTCGGATAAAATTAGCACAACGTAAACGACCCAAAGAACCCCCT
TCTGGTAGAATCATTGAGCACGATAACGATAGAGAGAATAAATCTTGAAGACAA
GCTTAGGTATTTATTCGGCGCAAAGTGCGTCGGGTGATGCTGCCAACTTAGTCGA
GCACCACCACCACCACCACTGAGATCCGGCTGCTAACAAAGCCCGAAAGGAAGC
TGAGTTGGCTGCTGCCACCGCTGAGCAATAACTAGCATAACCCCTTGGGGCCTCT
AAACGGGTCTTGAGGGGTTTTTTGCTGAAAGGAGGAACTATATCCGGATTGGCGA
ATGGGACGCGCCCTGTAGCGGCGCATTAAGCGCGGCGGGTGTGGTGGTTACGCG
CAGCGTGACCGNTACACTTGCCAGCGCCCTANCGCCCGCTCCTTTCGCTTTCTTTC
CCTTCCTTTCTCGCNACGTTCGCCGGCTTTCCCCGTCAGCTCTAAATCGGGGGGCT
CCCTTTAGNGTNCCGATTTAGTGCTTTACNGCACCTCNACCCCANNAACTTGATTT
AGGNNNATGGNTTCANCGTNNNGNGCCNATCNNCCCNGATAGACGGGNTTTTCG
CCCTNNNANNNTTGGGANNNNNNNNNTNNCTNNANTNNNNGGNNNNNCTNNNN
NNN 
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Sequencing CBU_1716 
CBU_1716_Reverse Sequence 
NNNNNNNNNNNNNNNNNCCNNNNNNNNTTGGACATGGAGGATAACGATATTATTGAGGCTCACA
GAGAACAGATTGGTGGTATGCCTTTGCATTATGGATCACAGATTGAAGAACATCACCAAGTGCG
CCAACGAGCGGGTATTTTTGATGTTTCTCACATGGGCGTTATCGACCTCGAAGGTGAAGAAGCT
ACTGCTTTTTTGCGTTATCTTTTAGCCAATGATGTTGCAAAACTCAGTGACGTCGGACGTGCTT
TGTATACCTGTATGCTTAACCCACAAGGCGGCGTTATCGATGATCTTATTGTTTATCGAGTGGC
GCCGACGGGTTATCGGTTAGTAGTGAACGCTGCAACGCGCGATAAAGACATCGCTTGGATAAAA
GAAAAAGGCGCTGGCTACAAGGTTTCAATTTCTGAACGCCCTGAAATGTGCATTCTTGCCGTTC
AAGGCCCACAAGCCATCGCTGCGGCTAAATCCATTTTTGATGAAGCGCTGTATGCGCAATTGGA
AGCCCTTAAACCTTTCCACTTTATTTCATCACCGACGCGAGATTTGCAAATAGCCCGAACAGGC
TACACGGGTGAAGATGGANTTGAAATAATTGTCCCCGCTTCTCGCGCGACGGATCTTTGGGCGC
GCTTCGTTCACCAGGGAGTGAAACCTTGTGGTTTAGGAGCACGCGATACCTTGCGCTTAGAANC
NNGTTTAAATTTTATATGGNACAGATATGGGACGAAACGACTTCTCNTTTTAATTTCCAATCTC
AGCTGGACGGTGTCCNGGNACGACNCGGNTCGNAATTNATANGTCGNNNNCNCCTTGGNAAAAA
CNANTTNGAACNANNAATNGNNCNNAAANAANCGANTCTTANNCGGGNTTTNNNNNN 
